Providence Swedish Neuroscience Institute (PSNI) reaches milestone in reducing global burden of glioblastoma.

{
  "signal_id": "0b367728-261f-43a7-8156-374b5ca4c28e",
  "signal_type": "news",
  "signal_subtype": "partners_with",
  "detected_at": "2026-06-09T00:00:00+00:00",
  "company": {
    "name": "Providence",
    "domain": "providence.org"
  },
  "data": {
    "url": "https://www.providence.org/news/uf/693213399?streamid=6707589",
    "title": "Providence Swedish Neuroscience Institute (PSNI) reaches milestone in reducing global burden of glioblastoma.",
    "excerpt": "Providence Swedish Neuroscience Institute (PSNI) reaches milestone in reducing global burden of glioblastoma.\n\nTuesday, June 9, 2026\n\nSEATTLE, WASH., June 8, 2026 - A collaboration involving Providence Swedish Neuroscience Institute (PSNI) recently concluded initial testing of a novel immunotherapy research project for the treatment of glioblastoma (GBM). This proprietary immunotherapeutic takes a unique approach to GBM treatment, maximizing the potential of a first-of-its-kind investigational agent by administering it directly into patients' tumors, rather than intravenously. GBM is an aggressive brain tumor for which there is no cure, with a median survival rate of 15-20 months.\n\nThis five-year research project is the culmination of more than 45 years of collective clinical research experience from neurosurgeon Charles Cobbs, M.D., research scientist Parvinder Hothi, Ph.D., and their team at the Ben and Catherine Ivy Center for Advanced Brain Tumor Treatment at Providence Swedish Neuroscience Institute.\n\n\"Other immunotherapies have only been administered via intravenous injection, meaning they can run rampant through the body, miss the tumor, or get blocked by the notorious blood-brain barrier,\" explains Dr. Cobbs. \"By targeting the tumor directly, we believe we can provide a more focused and safer treatment.\"\n\nGBM is known as an immunologically 'cold' tumor, where the tumor...",
    "summary": "Providence Health & Services partnered with HDT Biotech Corporation on Jun 8th '26.",
    "location": "Seattle, Washington, United States, Northern America, Americas",
    "planning": false,
    "image_url": "https://cdn.providence.org/asset/GtV28qX0x6P0DfEBf7sJ7w10/project/psjh/providence/socal/images/logos/providence-logo-svg/svg?h=38&iar=0&w=200&rev=3f439a997f8142a3906a5e99e27a8b4b&hash=116C8657600BE12BB61DC2895EF69434",
    "confidence": 0.2713,
    "published_at": "2026-06-09T00:00:00Z",
    "location_data": [
      {
        "city": "Seattle",
        "state": "Washington",
        "region": "Northern America",
        "country": "United States",
        "continent": "Americas",
        "fuzzy_match": false
      }
    ],
    "effective_date": "2026-06-08",
    "article_sentence": "To address this, Providence Swedish forged a collaboration with Seattle-based HDT Bio that activates and expands T-cell function in the tumor microenvironment.",
    "related_company_name": "HDT Biotech Corporation",
    "related_company_domain": "hdt.bio"
  }
}

curl https://signals.autobound.ai/v1/signals/0b367728-261f-43a7-8156-374b5ca4c28e \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"providence.org","limit":20}'